Pars Isotope Treatment Of Mtap Deleted Cancers Equipment & Supplies
3 equipment items found
by:Pars Isotope Co based inTehran, IRAN
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its characteristic as a gamma emitter, allowing not only for therapeutic intervention ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively target neuroendocrine tumor cells, facilitating their complete destruction. This procedure not only assists in treatment but also enhances diagnostic ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOPSMA kit is an innovative theranostic radiopharmaceutical developed by Parsisotope Company, designed specifically for the treatment of metastatic prostate cancer. This kit is notable for being the first of its kind globally, and is used in conjunction with the Lu-177 radioisotope. It targets prostate-specific membrane antigen (PSMA), a membrane glycoprotein, the expression of which ...